Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease

Elisabetta Ferrero, Angelo Corti, Julien Haroche, Daniela Belloni, Barbara Colombo, Alvise Berti, Giulio Cavalli, Corrado Campochiaro, Antonello Villa, Fleur Cohen-Aubart, Zahir Amoura, Claudio Doglioni, Lorenzo Dagna, Marina Ferrarini

Research output: Contribution to journalArticle

Abstract

Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis (LCH) characterized by tissue infiltration with CD68+ foamy histiocytes. TNF-related chronic inflammation and mutations in the MAP kinase signaling pathway in histiocytes are recognized as the two major pathogenic events. Among pleomorphic clinical manifestations, cardiovascular involvement is frequent and prognostically relevant. Evaluation of ECD clinical course and response to treatment is, however, still challenging. Taking advantage of the two largest cohorts of ECD patients worldwide, we investigated the relevance and the potential of circulating Chromogranin A (CgA), a pro-hormone involved in cardiovascular homeostasis and inflammation, as a biomarker of response to therapy in ECD. Consistent with other TNF-related inflammatory diseases, we found that not only TNF-α and soluble TNF-Receptors (sTNF-Rs), but also CgA plasma levels were significantly increased in ECD patients compared to controls. CgA, but not sTNF-Rs, discriminated cardiovascular involvement in ECD patients and correlated with pro-Brain Natriuretic Peptide (pro-BNP). In a single case, where a cardiac biopsy was available, CgA was found expressed by cardiomyocytes but not by infiltrating histiocytes. In four ECD patients, where serial determination of these parameters was obtained, the kinetics of sTNF-Rs and CgA paralleled response to therapy with anti-cytokine inhibitors; specifically, sTNF-Rs overlapped TNF-associated inflammation, while CgA, together with pro-BNP, closely mirrored response of cardiac disease. Our data indicate that both sTNF-Rs and CgA are linked to ECD pathophysiology. Moreover, CgA, in concert with pro-BNP, can be further exploited to fulfill the unmet clinical need of non-invasive reliable biomarkers of cardiac disease in these patients.

Original languageEnglish
JournalOncoImmunology
DOIs
Publication statusAccepted/In press - Jul 1 2016

Keywords

  • Chromogranin A
  • chronic inflammation
  • Erdheim–Chester disease
  • histiocytes
  • soluble TNF-Receptors
  • TNF-α

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease'. Together they form a unique fingerprint.

  • Cite this

    Ferrero, E., Corti, A., Haroche, J., Belloni, D., Colombo, B., Berti, A., Cavalli, G., Campochiaro, C., Villa, A., Cohen-Aubart, F., Amoura, Z., Doglioni, C., Dagna, L., & Ferrarini, M. (Accepted/In press). Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease. OncoImmunology. https://doi.org/10.1080/2162402X.2016.1181244